0
Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Ç×¾ÏÈ­Çпä¹ý ÈÄ ¹«¿ù°æ ¹ß»ý À¯¹æ¾Ï ȯÀÚÀÇ °»³â±â Áõ»ó°ú »îÀÇ Áú

Menopausal Symptoms and Quality of Life Among Breast Cancer Patients with Chemotherapy-induced Amenorrhea

Á¾¾ç°£È£¿¬±¸ 2019³â 19±Ç 2È£ p.90 ~ 97
KMID : 1035120190190020090
¹ÚÁøÈñ ( Park Jin-Hee ) - ¾ÆÁÖ´ëÇб³ °£È£´ëÇÐ

Á¤¿ë½Ä ( Jung Yong-Sik ) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ À¯¹æ¿Ü°ú
±èÁö¿µ ( Kim Ji-Young ) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ À¯¹æ¿Ü°ú
¹è¼±Çü ( Bae Sun-Hyoung ) - ¾ÆÁÖ´ëÇб³ °£È£´ëÇÐ
Á¶À¯Á¤ ( Jo Yu-Jung ) - ¾ÆÁÖ´ëÇб³ °£È£´ëÇÐ

Abstract

Purpose: The aim of this study was to evaluate the severity of menopausal symptoms and their impact on the quality of life (QOL) in breast cancer patients with chemotherapy-induced amenorrhea.

Methods: A cross-sectional survey design was used. Participants were 112 breast cancer patients with chemotherapy-induced amenorrhea. They completed the Menopause Rating Scale (MRS) and the Functional Assessment of Cancer Therapy-General (FACT-G). Data were analyzed using descriptive statistics, independent ttests, one-way ANOVA, Pearson¡¯s correlation coefficients, and multiple regression with SPSS/WIN 23.0.

Results: The prevalence of symptoms among the participants were as follows: sleep problems, 88.4%; physical and mental exhaustion, 80.4%; joint and muscular discomfort, 76.8%; and depression, 70.5%. Menopausal symptoms had a significant negative association with QOL. The results of the regression analysis showed that psychological and urogenital symptoms were statistically significant in explaining patients¡¯ QOL and accounted for 70% of the total variance.
Conclusion: Menopausal symptoms appear to be a significant problem for premenopausal breast cancer patients. Assessment and control of menopausal symptoms played a large role in maintaining the quality of life in breast cancer patients.
KeyWords
À¯¹æ¾Ï, °»³â±â, »îÀÇÁú, Ç×¾ÏÈ­Çпä¹ý
Breast neoplasms, Menopause, Quality of life, Drug therapy
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed